Skye Bioscience, Inc. · NASDAQ:SKYE
Skye Bioscience — H.C. Wainwright 23rd Annual Global Investment Conference (September 2021)
19 slides from Skye Bioscience's conference presentation, September 2021
Slide 1: Unlocking the Pharmaceutical Potential of Cannabinoids
Unlocking the Pharmaceutical Potential of Cannabinoids H.C. Wainwright 23rd Annual Global Investment Conference September 2021 • OTCQB: SKYE
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains “forward-looking statements”, All information contained in this presentation is provided as of including statements regarding Skye Bioscience, Inc. and its the date of the presentation and is subject to change without subsidiaries, within the meaning of th
Slide 3: Overview
Overview NOVEL TECHNOLOGY Biopharmaceutical company • Bioengineered, synthetic cannabinoid derivatives developing proprietary, synthetic designed to significantly enhance therapeutic benefits cannabinoid derivatives to treat INTELLECTUAL PROPERTY diseases with significant unmet • First-in-class pate
Slide 4: What is Glaucoma
What is Glaucoma Glaucoma is a disease that leads to the progressive damage of retinal ganglion cells, which make up the optic nerve, and without intervention will gradually lead to irreversible blindness A key risk factor of glaucoma involves increased pressure in the eye - intraocular pressure (IO
Slide 5: Opportunity to Transform the Treatment of Glaucoma
Opportunity to Transform the Treatment of Glaucoma IOP Class of Medication Generic Example MOA Potential Side Effects Reduction irritation, redness, blurred vision, dry eyes, • Current drugs aim to lower IOP in order Prostaglandins Latanoprost 30-35% ↑ Outflow light sensitivity, headaches, eyelash c
Slide 6: Relevance of THC to Glaucoma
Relevance of THC to Glaucoma • Cannabinoid receptors throughout the body play an important role in managing many vital body functions • Eye is rich with cannabinoid receptors, specifically in tissues involved in managing fluid production and drainage as well as cells responsible for vision • THC and
Slide 7: Multiple Independent Studies Demonstrate THC's Ability to Lower IOP
Multiple Independent Studies Demonstrate THC’s Ability to Lower IOP Y. Panahi et al. / Biomedicine & Pharmacotherapy 86 (2017) 620–627 skyebioscience.com • 7
Slide 8: Challenges to THC as an Effective Treatment of Glaucoma
Challenges to THC as an Effective Treatment of Glaucoma Systemic Delivery Local Delivery • Requires relatively high dose to achieve • THC is lipophilic - challenging to deliver therapeutic effect in the eye into and penetrate aqueous tissue, like the eye • Variable pharmacokinetics and pharmacodynam
Slide 9: SKYE's Approach Unlocks Therapeutic Value of THC
SKYE’s Approach Unlocks Therapeutic Value of THC Skye has developed a prodrug that allows local delivery into the eye, limiting systemic exposure and delivering THC to ocular tissue responsible for regulating IOP • Rational drug design and bioengineering used to develop a synthetic prodrug of THC, c
Slide 10: THCVHS Lower IOP Better than Top Market Leaders
THCVHS Lower IOP Better than Top Market Leaders In a preclinical model using New Zealand white rabbits: • THCVHS demonstrates superior decline in IOP versus latanoprost and timolol • THCVHS demonstrates superior duration of response Average IOP vs Time profile of Latanoprost (0.005%) vs THCVHS (1.0%
Slide 11: THCVHS can be Combined to Enhance Effects
THCVHS can be Combined to Enhance Effects In a preclinical model using Dutch Belted pigmented rabbits: • THCVHS alone demonstrates superior IOP-lowering and duration vs latanoprost • THCVHS with netarsudil further enhances IOP-lowering and duration of effect Average IOP vs Time profile of Latanopros
Slide 12: Multi-factorial Mechanism of Action
Multi-factorial Mechanism of Action • In an ex vivo model of human trabecular meshwork, the tissues responsible for fluid drainage, THC significantly lowered pressure and increased drainage in both healthy and diseased tissue • THC treatment also significantly reduced markers of fibrosis and inflamm
Slide 13: Not all Glaucoma Patients Have Elevated IOP
Not all Glaucoma Patients Have Elevated IOP • Large proportion of glaucoma patients % of glaucoma patients with normal IOP present with normal IOP, but still suffer progressive damage to optic nerve cells and vision loss • Not clear what causes neurodegeneration of optic nerve in these patients • A
Slide 14: Cannabinoids Demonstrate Neuroprotection
Cannabinoids Demonstrate Neuroprotection • Multiple studies, in different animal species & models, of glaucoma have demonstrated ability of cannabinoids to promote health and survival of optic nerve cells • Optic nerve injury model in rats planned to initiate in H2- 21 to validate neuroprotection pr
Slide 15: Management
Management Punit Dhillon Richard Janney Tu Diep, MSc Chief Executive Officer Principal Accounting Officer Sr Vice President, Development • 30 years of business experience and • Senior leaderships positions at • Co-founded and led OncoSec Medical, a served as a Vice President to CFO on Element Biosci
Slide 16: Board Directors & Advisors
Board Directors & Advisors Board of Director Clinical Advisors Scientific Advisors Punit Dhillon Robert Ritch, MD Giovanni Appendino, PhD Chair Professor of Ophthalmology, Mt. Sinai Professor of Organic Chemistry, U.Piedmont Former co-founder, CEO, and director of OncoSec Shelley and Steven Einhorn
Slide 17: Unique Competitive Position
Unique Competitive Position THCVHS demonstrates superior IOP lowering than market-leading glaucoma therapeutics Efficient first-in-human clinical trial leading to initiation of US Phase 2 in H2-22 Experienced management and eminent advisory boards Preclinical data suggests significant opportunities
Slide 18: Investor Day
Investor Day Date: October 12, 2021 Time: 10:00 a.m. PDT Skye’s management and advisory team take a deeper dive into our scientific approach and strategic development plan for 2022 skyebioscience.com • 18
Slide 19: To learn more please contact
To learn more please contact: Karam Takhar VP, Corporate Development & Investor Relations ir@skyebioscience.com 1 (858) 410-0266
Skye Bioscience — H.C. Wainwright 23rd Annual Global Investment Conference (September 2021) on 6ix